

Relistor (methylnaltrexone)
Effective 02/26/18

Plan	<input checked="" type="checkbox"/> MassHealth <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		<input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Specialty Limitations	N/A		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Relistor is indicated for opioid-induced constipation in adults with chronic noncancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g. weekly) opioid dosage escalation.

Coverage Guidelines

1. Member has a diagnosis of opioid-induced constipation (OIC) **AND**
2. Member has experienced an inadequate response or intolerance to treatment with at least two (2) different laxative agents (e.g., milk of magnesia, lactulose, polyethylene glycol [PEG], psyllium, senna, bisacodyl, etc.) **AND**
3. Member has experienced an inadequate response or intolerance to treatment with Amitiza[®] (lubiprostone).

Limitations

1. Approvals will be granted for 12 months.

References

1. Relistor (methylnaltrexone) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals Inc; March 2018
2. Thomas J, Karver S, Cooney GA et al. Methylnaltrexone for opioid-induced constipation in advanced disease. N Engl J Med. 2008; 358:2332-2343.
3. Michna E, Blonsky ER, Schulman S, Tzanis E, Manley A, Zhang H, et al. Subcutaneous methylnaltrexone for treatment of opioid- induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. Journal of Pain. 2011;12(5):554-62.



4. Anissian L, Schwartz HW, Vincent K, Vincent HK, Carpentino J, Stambler N, et al. Subcutaneous methylnaltrexone for treatment of acute opioid-induced constipation: phase 2 study in rehabilitation after orthopedic surgery. *Journal of hospital Medicine*. 2012;7(2):67-72.
5. Rodrigues A, Wong C, Mattiussi A, Alexander S, Lau E, Dupuis LL. Methylnaltrexone for opioid-induced constipation in pediatric oncology patients. *Pediatric Blood & Cancer*. 2013;60(10):1667-70.
6. Ford AC, Brenner DM, Schoenfeld PS. Efficacy or Pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis. *American Journal of Gastroenterology*. 2013;108(10):1566-74.
7. Spierings ELH, Drossman DA, Cryer B, et al. Efficacy and Safety of Lubiprostone in Patients with Opioid-Induced Constipation: Phase 3 Study Results and Pooled Analysis of the Effect of Concomitant Methadone Use on Clinical Outcomes. *Pain Med* 2018; 19:1184.
8. Webster LR, Michna E, Khan A, et al. Long-Term Safety and Efficacy of Subcutaneous Methylnaltrexone in Patients with Opioid-Induced Constipation and Chronic Noncancer Pain: A Phase 3, Open-Label Trial. *Pain Med* 2017; 18:1496.

Review History

00/00/09 – Implemented
02/23/09 – Reviewed
02/20/10 – Reviewed
02/22/10 – Reviewed
02/28/11 – Reviewed
02/27/12 – Reviewed
02/25/13 – Reviewed
02/24/14 – Reviewed
02/23/15 – Reviewed
02/22/16 – Updated
02/27/17 – Reviewed
02/26/18 – Reviewed

Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.